BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

AI models trained on optical coherence tomography scans to detect eye diseases are showing promise in diagnosing heart ...

NEW YORK – Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of a subcutaneous formulation of its PD-1 ...

NEW YORK – The US Food and Drug Administration on Friday expanded the indication for Novartis' radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for use prior to chemotherapy in ...

With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Thursday recommended against marketing authorization for Eli Llilly's Alzheimer's drug Kisunla ...

The firm said its next-generation siRNA candidate showed in preclinical studies that it could reduce tumor growth and metastatic spread.

Early clinical results suggest the firm's antibodies targeting the Vβ T-cell receptor could induce strong and durable responses in cancer patients.

The Series B financing will support an upcoming clinical trial in New Zealand of the company's lead program, EPI-321, in facioscapulohumeral muscular dystrophy.